CDK4 and breast cancer: The primary objective of this study was to describe the demographics and characteristics, treatment patterns, and clinical outcomes of Japanese patients with advanced HR+, HER2− breast cancer who were prescribed CDK4 and 6 inhibitors, using a large claims-based database.